Bio-Mix is a program created by Teva together with i8 Ventures as part of the National Forum for Bio-Innovators where doctoral and post-doctoral students from leading universities in Israel learn to connect academic research with the “real life” business world. The program is led by Professor Yesha Sivan, founder and CEO of i8 Ventures and DigitalRosh, and Dr. Dana Bar-On, director of Teva’s academic relations in the global R&D department.
The 4th year of the program will start with an all-day opening event on January 26, 2023. This event, on top of professional lectures, brainstorming, and networking, will serve as the graduation ceremony for the BioInnovators Class of 2022 and a Welcome event for the Class of 2023, with online greetings from Mr. Isaac Herzog, President of the State of Israel, Mr. Richard Francis, President & CEO of Teva, and Dr. Eric Hughes, EVP, Head of R&D at Teva.
In this opening event titled “Teva and Israeli Academia: Partners from the First Step” Teva and collaborators from the academia, medical centers, start-ups, and the government will gather for a vibrant scientific brainstorming and networking event of advancing academic innovation into drug discovery. On the agenda: A keynote lecture by Dr. Steffen Nock, SP, Head of Biosimilars & Chief Science Officer at Teva. Professional sessions on Neuroscience and Immunotherapy will be led by leading researchers from the Technion, Tel Aviv University, Haifa University, and Weizmann Institute.
